✦ LIBER ✦

Expressivity of a common fragile site, fra(3)(p14.2), in patients with cancer and other diseases

✍ Scribed by Motoi Murata; Mikako Otsuka; Yukiko Hayakawa; Ei-ichi Takahashi; Hideo Tsuji; Tada-aki Hori

Publisher: Nature Publishing Group
Year: 1992
Tongue: English
Weight: 513 KB
Volume: 37
Category: Article
ISSN: 1435-232X
DOI: 10.1007/bf01900714

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A population cytogenetic study of a comm

A population cytogenetic study of a common fragile site, fra(3)(p14), in a healthy population

✍ Motoi Murata; Mikako Otsuka; Yukiko Hayakawa; Ei-ichi Takahashi; Hideo Tsuji; Ta 📂 Article 📅 1990 🏛 Nature Publishing Group 🌐 English ⚖ 604 KB

Chromosomal fragile sites FRA3B and FRA1

Chromosomal fragile sites FRA3B and FRA16D show correlated expression and association with failure of apoptosis in lymphocytes from patients with thyroid cancer

✍ Isabella Sbrana; Franca Veroni; Maria Nieri; Aldamaria Puliti; Roberto Barale 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 163 KB

## Abstract It has been suggested that common fragile sites (cFSs) are related to cancer development. This appears to be the case for FRA3B and FRA16D, localized in two tumor‐suppressor genes (__FHIT__ and __WWOX__, respectively) that are altered by deletions or loss of heterozygosity (LOH) in many

Precise localization of the FHIT gene to

Precise localization of the FHIT gene to the common fragile site at 3p14.2 (FRA3B) and characterization of homozygous deletions within FRA3B that affect FHIT transcription in tumor cell lines

✍ S. Tiong Ong; Kwun M. Fong; Scott A. Bader; John D. Minna; Michelle M. Le Beau; 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 154 KB 👁 2 views

Chromosomal or allelic losses at 3p14 are common in a variety of human tumors, including those of the lung, breast, kidney, and head and neck. This suggests the existence of a tumor suppressor gene in this band. A promising candidate is the recently cloned FHIT gene, which spans the common fragile s

The colorimetric determination of leucin

The colorimetric determination of leucine aminopeptidase in urine and serum of normal subjects and patients with cancer and other diseases

✍ Julius A. Goldbarg; Alexander M. Rutenburg 📂 Article 📅 1958 🏛 John Wiley and Sons 🌐 English ⚖ 698 KB

HE FIRST demonstration of "leucylpepti-T dase" as a component of erepsin was made by measuring the rate of liberation of carboxyl groups from L-leucylglycine.6 However, since this substrate was hydrolyzed by enzymes other than leucylpeptidase, L-leucinamide, a more specific substrate was synthesized

Aberrant promoter methylation of p16INK4

Aberrant promoter methylation of p16INK4a, RARB2 and SEMA3B in bronchial aspirates from patients with suspected lung cancer

✍ Hans J. Grote; Viola Schmiemann; Helene Geddert; Ulrich P. Rohr; Rainer Kappes; 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 French ⚖ 158 KB

Aberrant promoter methylation of normally unmethylated CpG-islands offers a promising tool for the development of molecular biomarkers. We investigated bronchial aspirates of patients admitted for suspected lung cancer with regard to the prevalence of aberrant methylation of potential marker genes.

MDM2 SNP309 T>G alone or in combination

MDM2 SNP309 T>G alone or in combination with the TP53 R72P polymorphism does not appear to influence disease expression and age of diagnosis of colorectal cancer in HNPCC patients

✍ Bente A. Talseth; Cliff Meldrum; Janina Suchy; Grzegroz Kurzawski; Jan Lubinski; 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 French ⚖ 64 KB 👁 1 views

## Abstract Disease expression in hereditary nonpolyposis colorectal cancer (HNPCC) cannot be readily explained by mutation site in the respective DNA mismatch repair genes associated with this disorder. One explanation is the role of modifying genes that can either promote or prevent disease devel